Literature DB >> 30826555

Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population.

Kavish Ihtisham1, Bhargavi Ramanujam1, Shivani Srivastava1, Narinder Kumar Mehra2, Gurvinder Kaur3, Neena Khanna4, Satish Jain5, Sachin Kumar6, Bhavna Kaul7, Raghavan Samudrala7, Manjari Tripathi8.   

Abstract

PURPOSE: Aromatic antiepileptic drugs (AEDs) are frequently implicated in cutaneous adverse drug reactions (cADRs), a few of which are associated with certain human leukocyte antigen (HLA) alleles in some populations. We aimed to find HLA-associations with AED-related cADRs among North Indians.
METHODS: North Indian subjects with cADR due to an AED, and those who were AED-tolerant were recruited as cases and controls, respectively. Genotyping for HLA-A, B and DRB1 were performed. Statistical analysis to compare carrier-rates and allele-frequencies between cases and controls (and healthy population, where necessary), was done for HLA-alleles occurring more than twice in either group.
RESULTS: 120 cases {11 - Lamotrigine (LTG), 14 -Valproic acid (VPA), 8 -Levetiracetam (LEV), 35 -Carbamazepine (CBZ) and 52 - Phenytoin (PHT)}, and 250 controls were recruited. Presence of HLA-A*31:01 and HLA-B*51:01 were found to increase the risk of Maculopapular exanthema (MPE) due to CBZ and PHT (OR = 6.38; 95% CI: 1.46-27.75; OR = 4.60; 95% CI: 1.54-13.72, respectively). Among the severe cADRs, HLA-B*57:01(OR = 11.00 95% CI: 1.41-85.81) and HLA-DRB1*07:01 (OR = 7.25; 95% CI: 1.09-48.18) were noted to be significantly associated with CBZ-induced Stevens Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN); HLA-B *51:01 was associated with drug reaction eosinophilia and systemic symptoms (DRESS) caused by PHT (OR = 6.90; 95% CI: 1.38-34.29).
CONCLUSIONS: We found significant associations of some HLA alleles with specific cADRs to CBZ and PHT in North Indians, which may need to be tested before AED-initiation; only screening for HLA-B*15:02 may not help in this population.
Copyright © 2019 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiepileptic drugs; Drug reaction eosinophilia and systemic symptoms (DRESS); Human leukocyte antigen (HLA); Maculopapular exanthema (MPE); Stevens-Johnson syndrome (SJS); Toxic Epidermal Necrolysis (TEN)

Mesh:

Substances:

Year:  2019        PMID: 30826555     DOI: 10.1016/j.seizure.2019.02.011

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  8 in total

1.  Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines.

Authors:  Lisanne E N Manson; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

2.  Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in Thailand.

Authors:  Napatrupron Koomdee; Chiraphat Kloypan; Pimonpan Jinda; Jiratha Rachanakul; Thawinee Jantararoungtong; Rattanaporn Sukprasong; Santirhat Prommas; Nutthan Nuntharadthanaphong; Apichaya Puangpetch; Maliheh Ershadian; Shobana John; Mohitosh Biswas; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

Review 3.  Genetic Markers for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the Asian Indian Population: Implications on Prevention.

Authors:  Swapna S Shanbhag; Madhuri A Koduri; Chitra Kannabiran; Pragnya R Donthineni; Vivek Singh; Sayan Basu
Journal:  Front Genet       Date:  2021-01-12       Impact factor: 4.599

4.  Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis.

Authors:  Mohitosh Biswas; Maliheh Ershadian; John Shobana; Ai-Hoc Nguyen; Chonlaphat Sukasem
Journal:  Clin Transl Sci       Date:  2022-05-22       Impact factor: 4.438

Review 5.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Authors:  Jason H Karnes; Allan E Rettie; Andrew A Somogyi; Rachel Huddart; Alison E Fohner; Christine M Formea; Ming Ta Michael Lee; Adrian Llerena; Michelle Whirl-Carrillo; Teri E Klein; Elizabeth J Phillips; Scott Mintzer; Andrea Gaedigk; Kelly E Caudle; John T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2020-09-06       Impact factor: 6.875

Review 6.  Genetic Landscape of Common Epilepsies: Advancing towards Precision in Treatment.

Authors:  Sarita Thakran; Debleena Guin; Pooja Singh; Priyanka Singh; Samiksha Kukal; Chitra Rawat; Saroj Yadav; Suman S Kushwaha; Achal K Srivastava; Yasha Hasija; Luciano Saso; Srinivasan Ramachandran; Ritushree Kukreti
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

7.  HLA-A∗24:02 associated with lamotrigine-induced cutaneous adverse drug reactions: A systematic review and meta-analysis.

Authors:  Wanshu Li; Jie Wang; Hangjuan Lin; Gang Shen
Journal:  Medicine (Baltimore)       Date:  2020-12-24       Impact factor: 1.817

8.  Impact of ABCB1 Polymorphism on Levetiracetam Serum Concentrations in Epileptic Uygur Children in China.

Authors:  Ting Zhao; Jing Yu; Ting-Ting Wang; Jie Feng; Wen-Bo Zhao; Li Sun; Lu-Hai Yu; Hong-Jian Li; Yan Sun
Journal:  Ther Drug Monit       Date:  2020-12       Impact factor: 3.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.